{"entity":{"id":"nct06549595","kind":"trial","name":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","aka":[],"tldr":"A phase 3 trial of AZD0486 in follicular lymphoma, run by AstraZeneca, now recruiting.","summary":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients is a phase 3 interventional study registered as NCT06549595 by AstraZeneca, with 1018 participants planned, started 2024-08-07 and due to reach its primary completion in 2031-11-26. Interventions recorded: Surovatamig, R-CHOP, R-CVP, BR. Conditions listed: Untreated Follicular Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06549595","url":"https://clinicaltrials.gov/study/NCT06549595"}],"tags":["ctgov-ingest"],"related":[],"cancers":["follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["azd0486"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06549595","phase":"3","setting":"A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)","sponsor":"AstraZeneca","enrolled":1018,"outcomes":[]},"route":"/trials/nct06549595/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"drug":[{"id":"azd0486","kind":"drug","name":"AZD0486","route":"/drugs/azd0486/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}